acipimox and Hypoglycemia

acipimox has been researched along with Hypoglycemia* in 3 studies

Trials

1 trial(s) available for acipimox and Hypoglycemia

ArticleYear
Suppression of lipolysis in normal man does not inhibit recovery from insulin-induced hypoglycaemia.
    European journal of clinical investigation, 1993, Volume: 23, Issue:1

    Pharmacological suppression of lipolysis is being increasingly used in the treatment of diabetic hyperlipidaemia. Although theoretical hazard of such treatment is that recovery from hypoglycaemia might be impaired. Seven normal subjects were therefore studied on two occasions, following treatment with a single dose of either acipimox 250 mg or placebo. Hypoglycaemic recovery was unaffected, despite effective suppression of plasma non-esterified fatty acid levels with acipimox. The results suggest that under these conditions activation of lipolysis may not be essential to recovery from hypoglycaemia.

    Topics: Acetoacetates; Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glycerol; Humans; Hyperlipidemias; Hypoglycemia; Hypolipidemic Agents; Insulin; Lipolysis; Male; Pyrazines

1993

Other Studies

2 other study(ies) available for acipimox and Hypoglycemia

ArticleYear
Importance of catecholamines in defense against insulin hypoglycemia in humans.
    Advances in pharmacology (San Diego, Calif.), 1998, Volume: 42

    Topics: Blood Glucose; Epinephrine; Fatty Acids, Nonesterified; Glucagon; Glucose; Glycerol; Heparin; Homeostasis; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypolipidemic Agents; Insulin; Lipolysis; Phentolamine; Propranolol; Pyrazines

1998
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans.
    Diabetologia, 1993, Volume: 36, Issue:11

    It is controversial as to whether ketone bodies are utilized by the human brain as a fuel alternative to glucose during hypoglycaemia. To clarify the issue, we studied 10 normal volunteers during an experimental hypoglycaemia closely mimicking the clinical hypoglycaemia of patients with Type 1 (insulin-dependent) diabetes mellitus or insulinoma. Hypoglycaemia was induced by a continuous infusion of insulin (0.40 mU.kg-1.min-1 for 8 h, plasma insulin approximately 180 pmol/l) which decreased the plasma glucose concentration to approximately 3.1 mmol/l during the last 3 h of the studies. Subjects were studied on two occasions, i.e. spontaneous, counterregulatory-induced post-hypoglycaemic increase in 3-beta-hydroxybutyrate (from approximately 0.2 to approximately 1.1 mmol/l at 8 h), or prevention of post-hypoglycaemic hyperketonaemia (plasma beta-hydroxybutyrate approximately 0.1 mmol/l throughout the study) after administration of acipimox, a potent inhibitor of lipolysis. In the latter study, glucose was infused to match the hypoglycaemia observed in the former study. The glycaemic thresholds and overall responses of counterregulatory hormones, symptoms (both autonomic and neuroglycopenic), and deterioration of cognitive function (psychomotor tests) were superimposable in the control study in which ketones increased spontaneously after onset of hypoglycaemic counterregulation, as compared to the study in which ketones were suppressed (p = NS). The fact that responses of counterregulatory hormones, symptoms and deterioration in cognitive function were not exaggerated when posthypoglycaemic hyperketonaemia was prevented, indicate that during hypoglycaemia, the counterregulatory-induced endogenous hyperketonaemia does not provide the human brain with an alternative substrate to glucose. Thus, it is concluded that during hypoglycaemia, endogenous hyperketonaemia does not contribute to brain metabolism and function.

    Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Brain; Cognition; Diabetes Mellitus, Type 1; Female; Glycerol; Homeostasis; Hormones; Humans; Hydroxybutyrates; Hypoglycemia; Hypolipidemic Agents; Insulin; Insulinoma; Ketone Bodies; Lactates; Lipolysis; Male; Pancreatic Neoplasms; Pyrazines; Reaction Time

1993